3-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors: A New Class of Cholesterol-Lowering Agents
Authors: D J Gordon, B M Rifkind
Journal: Annals of Internal Medicine (1987)

Editorials1 November 19873-Hydroxy-3-methylglutaryl Coenzyme A (HMG-CoA) Reductase Inhibitors: A New Class of Cholesterol-Lowering AgentsDAVID J. GORDON, M.D., Ph.D., BASIL M. RIFKIND, M.D.DAVID J. GORDON, M.D., Ph.D.Search for more papers by this author, BASIL M. RIFKIND, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-107-5-759 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe food and drug Administration's recent approval of lovastatin, the first of a new class of powerful cholesterol-lowering agents, the 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors, occurs at a time when physicians' attitudes and practices for identifying and treating high cholesterol levels in blood are markedly changing. In 1984, the Lipid Research Clinics Coronary Primary Prevention Trial (CPPT) showed that cholestyramine-induced cholesterol lowering reduces the risk for coronary heart disease (1). Confirming the predictions of population-based observational studies such as the Framingham Study, the CPPT showed that each 1% reduction in cholesterol levels results in an approximate 2% reduction in risk...References1. . The Lipid Research Clinics Coronary Primary Prevention Trial Results: I. Reduction in incidence of coronary heart disease. JAMA. 1984;251:351-64. CrossrefMedlineGoogle Scholar2. . The Lipid Research Clinics Coronary Primary Prevention Trial Results: II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA. 1984;251:365-74. CrossrefMedlineGoogle Scholar3. BLANKENHORNNESSIMJOHNSONSANMARCOAZENCASHIN-HEMPHILL DSRMSL. Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA. 1987;257:3233-40. CrossrefMedlineGoogle Scholar4. Consensus Conference Statement on lowering blood cholesterol to prevent heart disease. JAMA. 1985;253:2080-6. CrossrefMedlineGoogle Scholar5. . Strategy for the prevention of coronary heart disease: a policy statement for the European Atherosclerosis Society. Eur Heart J 1987;8:77-88. Google Scholar6. ENDOKURODOTSUJITA AMG. ML236A, ML-236B, and ML 236C, new inhibitors of cholesterol-genesis produced by Penicillium citrinum. J Antibiot (Tokyo). 1976;29:1346-8. CrossrefMedlineGoogle Scholar7. ALBERTSCHENKURON AJG. Mevinolin: a highly potent competitive inhibitor of 3-hydroxy-3-methyl-glutaryl coenzyme A reductase and a cholesterol-lowering agent. Proc Natl Acad Sci USA. 1980;77:3957-61. CrossrefMedlineGoogle Scholar8. . Therapeutic response to lovastatin (mevinolin) in non-familial hypercholesterolemia: a multicenter study. JAMA. 1986;256:2829-34. CrossrefMedlineGoogle Scholar9. HOEGMAHERZECH JML. Effectiveness of mevinolin on plasma lipoprotein concentrations in type II hyperlipoproteinemia. Am J Cardiol. 1986;57:933-9. CrossrefMedlineGoogle Scholar10. NAKAYAHOMMATAMACHISHIGEMATSUHATAGOTO NYHHYY. The effect of CS-514 on serum lipids and apolipoproteins in hypercholesterolemic subjects. JAMA. 1987;257:3088-93. CrossrefMedlineGoogle Scholar11. MAGILSUDHOFBILHEIMERGOLDSTEINBROWN PGJDJM. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in liver of hamsters and rabbits. Proc Natl Acad Sci USA. 1986;83:8370-4. CrossrefMedlineGoogle Scholar12. VEGAGRUNDY GS. Treatment of primary moderate hypercholesterolemia with lovastatin (mevinolin) and colestipol. JAMA. 1987;257:33-8. CrossrefMedlineGoogle Scholar13. KRITCHEVSKY D. Inhibition of cholesterol synthesis. J Nutr. 1987;117:1330-4. CrossrefMedlineGoogle Scholar14. HUNNINGHAKEGORDONTAMIRRIFKIND DDIB. Management of hyperlipoproteinemia. In: PRADHAN SN, MAICKEL RP, DUTTA SN, eds. Pharmacology in Medicine. Bethesda: SP Press International Inc. ; 1986:617-33. Google Scholar15. MABUCHITABATATAMI HTR. Effects of an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase on serum lipoproteins and ubiquinone-10 levels in patients with familial hypercholesterolemia. N Engl J Med. 1981;305:478-82. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: National Heart, Lung, and Blood Institute National Institutes of Health Bethesda, Maryland PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySafety of fluvastatin in patients undergoing high-risk non-cardiac surgeryTherapeutic Compounds in Nature as Leads for New PharmaceuticalsNatural Products as Leads for New PharmaceuticalsThe Influence of Legume Seeds on Human Plasma Lipid ConcentrationsPreclinical evaluation of lovastatinCatabolic Response to Lovastatin TherapyBennett P. Lustgarten, MD 1 November 1987Volume 107, Issue 5Page: 759-761KeywordsBloodCholesterolCoenzymesCoronary heart diseaseFood and Drug AdministrationHypercholesterolemiaLipidsObservational studies Issue Published: 1 November 1987 PDF DownloadLoading ...